<DOC>
	<DOCNO>NCT02605525</DOCNO>
	<brief_summary>The purpose study assess efficacy safety SM101 treatment Immunoglobulin A nephropathy ( IgAN )</brief_summary>
	<brief_title>Efficacy Safety SM101 Treatment IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>1 . 18 year age old time screen 2 . Participant may race ethnicity 3 . Participant must biopsyproven diagnosis IgAN . 4 . Participant 's blood pressure ≤130/80 mmHg Screening 5 . Participant maximally tolerate dose angiotensinconverting enzyme ( ACE ) inhibitor and/or angiotensin receptor blocker ( ARB ) least 3 month prior baseline visit . 6 . Participant must present screen current proteinuria level 1 g/24 h 3.5 g/24 h , base spot urine proteintocreatinine ratio ( UPCR ) 7 . Participant must present screen estimate glomerular filtration rate ( eGFR ) &gt; 40mL/min/1.73m^2 8 . If female childbearing potential , participant must negative pregnancy test screening , currently breastfeed , agree employ adequate birth control measure duration study . Male participant female partner childbearing potential must agree use adequate birth control measure duration study 9 . Participant willing able comply requirement protocol agree sign informed consent form prior studyrelated activity 1 . Participant history current evidence renal disease IgAN 2 . Participants evidence rapidly progressive disease 3 . Participant IgAN histologic evidence advance tubular atrophy interstitial 4 . History current evidence autoimmune disease 5 . History current evidence chronic uncontrolled medical condition could , opinion Investigator , affect participant 's safety ability adhere protocol 6 . History current evidence severe acute chronic infection 7 . Use systemic corticosteroid within 3 month prior baseline , anticipate use treatment period ( Week 1 Week 4 ) . Note : Corticosteroids administer inhalation intranasally , limited topical use lowpotency topical corticosteroid allow throughout study . 8 . Known hypersensitivity allergic reaction E. coliderived recombinant product , yeast extract , IP excipients 9 . Treatment immunomodulatory/immunosuppressive compound monoclonal antibody indication within 6 month ( unless otherwise state ) prior screen ( eg , B celldepleting agent [ eg , rituximab , epratuzumab ] ≥48 week ; Bcell modify agent [ eg , belimumab , atacicept ] ≥24 week ; IV immunoglobulins ≥12 week immunosuppressive treatment [ eg , methotrexate , cyclophosphamide , cyclosporine , tacrolimus , mycophenolate mofetil , azathioprine ] ≥12 week ) 10 . Clinically significant laboratory abnormality prior baseline 11 . History malignancy within past 5 year prior screen ( except basal squamous cell carcinoma skin , situ cervical cancer , stable prostate cancer require treatment ) 12 . History tonsillectomy within 2 month prior screen 13 . Participation another clinical study involve IP investigational device within 30 day prior screen schedule participate another clinical study involve IP investigational device course study 14 . Participant family member employee Investigator 15 . A female participant pregnant nursing time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IgAN</keyword>
</DOC>